Developing new oral rotavirus vaccine

March 26, 2012

The University of Otago is playing a major role in the international development of a new low-cost oral vaccine to protect newborn babies against rotavirus.

Rotavirus "gastro" is a life-threatening that results in the death of over half a million children under five worldwide and two million hospitalisations each year. In New Zealand, rotavirus is responsible for 1500 of children under five years of age each year.

The research collaboration led by the Murdoch Children’s Research Institute at the Royal Children’s Hospital, Melbourne, is supported by the New Zealand Health Research Council and its Australian counterpart the National Health and Medical Research Council. The Dunedin Clinical Trial Team at the University of Otago began the second phase of the development in January this year.

University of Otago researcher, Dr Pam Jackson, from the Department of Women’s and Childrens’ Health, said that one dose of the was well tolerated in the first phase of development in the Melbourne-based trial in babies, which was completed last year.

In the second phase of development of the vaccine, newborn babies and infants in Dunedin will be given three doses of the , called RV3-BB, or a placebo to ascertain the level of immunity to rotavirus generated by the vaccine. The vaccine is derived from a harmless strain of rotavirus found in newborn babies.

Children who have had this strain show no symptoms, and have shown to be protected against future infection by rotavirus strains.

Dr. Jackson said that unlike the current rotavirus vaccines that are available which are given to babies six to eight weeks of age, this vaccine will be given to newborns.

“This is important because we know that infection can occur very early in developing countries and means that the vaccine has the potential to save many thousands of lives by vaccinating at birth while babies are still in a health care setting,” she says.

“After this time, babies are often lost track of, when their risk of the severe rotavirus disease is very high. By starting vaccination from birth we will be potentially able to offer them protection from rotavirus disease by three months of age.”

At present in New Zealand and many other countries, the currently available vaccines are not part of the National Immunisation Programme of funded vaccinations, mainly due to cost.

The research and development of this vaccine is being led and conducted by academic institutions rather than the pharmaceutical industry with the intention to partner with developing country manufacturers so that the vaccine will ultimately become available at lower cost for developing countries, where they are needed most.

Dr. Jackson says that there is significant potential benefit of a lower cost, effective vaccine for from birth in developing nations, and also to the healthcare system, children and their parents in developed nations such as New Zealand.
In the next few months, expectant parents will be given information about the trial and asked whether they wish to participate.

“This oral vaccine has been shown to be well tolerated. What we now need to know is how effective the vaccine is at protecting against the disease and how long protection lasts.”

Explore further: Rotavirus vaccine greatly reduced gastroenteritis hospitalizations in children

Related Stories

Rotavirus vaccine greatly reduced gastroenteritis hospitalizations in children

June 24, 2011
Vaccination against rotavirus, a major cause of severe acute gastroenteritis in children, dramatically decreased hospitalization rates for the infection among infants in three U.S. counties, according to a new study published ...

Study shows updated rotavirus vaccine not linked to increase in bowel obstruction

January 4, 2012
The rotovirus vaccine was pulled from the marketplace in 1999 after being associated with painful gastrointestinal complications, however, the updated rotavirus vaccines do not appear to increase the occurrence of these potentially ...

Rotavirus vaccination of infants also protects unvaccinated older children and adults

August 30, 2011
Vaccinating infants against rotavirus also prevents serious disease in unvaccinated older children and adults, according to a study by the Centers for Disease Control and Prevention (CDC). This helps reduce rotavirus-related ...

Recommended for you

Vaccinating against psoriasis, allergies and Alzheimer's a possibility, research shows

October 23, 2017
Research from the Universities of Dundee and Oxford has shown how combining the tetanus vaccine with a viral particle that normally affects cucumbers can be used to treat psoriasis and allergies, and may even protect against ...

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.